Welcome to our dedicated page for Solventum Corporation news (Ticker: SOLV), a resource for investors and traders seeking the latest updates and insights on Solventum Corporation stock.
Solventum Corporation (NYSE: SOLV) generates a steady flow of news that reflects its role in the medical instruments and supplies sector and its focus on MedSurg, Dental Solutions and Health Information Systems. News about Solventum often highlights developments in advanced wound care, portfolio changes, capital allocation decisions and strategic initiatives intended to support long-term growth.
Recent announcements include agreements and completion of the acquisition of Acera Surgical, a bioscience company focused on fully engineered materials for regenerative wound care. These updates describe how Solventum is expanding its MedSurg portfolio into the synthetic tissue matrices technology space within acute care settings. Other news covers clinical and scientific developments, such as international consensus recommendations on the use of closed incision negative pressure therapy with reticulated open cell foam dressings, which relate directly to Solventum Prevena Therapy and its application across surgical specialties.
Investors and healthcare professionals following SOLV news will also see coverage of financial results, including quarterly earnings releases and guidance updates, as well as information about Solventum’s “Transform for the Future” initiative to reshape its cost structure and support innovation. Capital markets and balance sheet actions, such as cash tender offers for outstanding notes, the sale of the purification and filtration business to Thermo Fisher Scientific Inc., and the authorization of a share repurchase program, are reported through both press releases and SEC filings.
Additional news items may feature recognition of operational capabilities, such as the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative for supply chain strength in the MedSurg segment, and participation in healthcare investor conferences. By reviewing the SOLV news feed on a regular basis, readers can track how Solventum’s strategic decisions, clinical evidence, portfolio moves and financial performance are communicated to the market over time.
Solventum (NYSE: SOLV) said its executives will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, Nov. 12, 2025, beginning at approximately 11:20 a.m. EST in New York, NY.
A live replay and archived recording will be available on the company's investor website at investors.solventum.com.
Solventum (NYSE: SOLV) appointed Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role she will oversee global commercial and R&D operations for MedSurg, Dental Solutions and Health Information Systems and will report to CEO Bryan Hanson.
Ms. Knight brings over 30 years of MedTech leadership, most recently serving as COO at Baxter where she led global sales, R&D, supply chain and regulatory affairs. Chris Barry, Executive VP and Group President of MedSurg, will depart effective December 31, 2025. The company said the change does not impact financial guidance and will provide an update with third quarter results in early November.
Solventum (NYSE: SOLV) will report third quarter fiscal 2025 results on Thursday, Nov. 6, 2025, released after U.S. market close. Management will host a live webcast the same day to discuss results and business updates.
Webcast details: Nov. 6, 2025 • 3:30 p.m. CST / 4:30 p.m. EST. Access via https://investors.solventum.com or by phone at US +1 (800) 715-9871, international +1 (646) 307-1963, Conference ID 6342275. A replay, press release, presentation slides, and supplemental financial disclosures will be posted on the Investor Relations website.
Solventum (NYSE: SOLV) has announced the pricing terms for its upsized note tender offers totaling $2.0 billion in aggregate purchase price. The company is offering to purchase multiple series of outstanding notes across two pools: Pool 1 with a maximum amount of $1.5 billion and Pool 2 with a maximum amount of $500 million.
For Pool 1, Solventum expects to accept approximately $650 million of the 5.450% Senior Notes due 2027 (69.35% proration) and $797.3 million of the 5.400% Senior Notes due 2029 (61.24% proration). In Pool 2, about $457.6 million of the 6.000% Senior Notes due 2064 and $21.9 million of the 5.900% Senior Notes due 2054 will be accepted. Settlement is expected on September 10, 2025.
Solventum (NYSE:SOLV) announced modifications to its previously announced tender offers, increasing the aggregate purchase cap from $1.75 billion to $2.0 billion. The company has also increased the Pool 1 Maximum Amount from $1.25 billion to $1.5 billion and raised the Tender SubCap from $500 million to $650 million.
As of the Early Tender Date (September 5, 2025), the offers were significantly oversubscribed. Solventum expects to accept the 5.450% Notes due 2027, 5.400% Notes due 2029, and 5.900% Notes due 2054 for purchase on a prorated basis. Due to oversubscription, the company does not expect to accept any Notes tendered after the Early Tender Date. Settlement is expected on September 10, 2025.
Thermo Fisher Scientific (NYSE: TMO) has completed its acquisition of Solventum's Purification & Filtration business for $4.0 billion in cash. The acquired business, now renamed as Thermo Fisher's Filtration and Separation business, will be integrated into the Life Sciences Solutions segment.
The acquisition strengthens TMO's bioproduction portfolio with advanced filtration technologies and expands its reach into industries requiring ultra-pure water. The acquired business is expected to generate $750 million in revenue for 2025 and achieve mid- to high-single digit organic growth. The transaction is projected to be dilutive to adjusted EPS by $0.06 in the first year, with expected synergies of $125 million in adjusted operating income by year five.
Solventum (NYSE: SOLV) has completed the sale of its Purification & Filtration (P&F) business to Thermo Fisher Scientific (NYSE: TMO) for $4.0 billion in cash. The company will receive net proceeds of $3.4 billion, primarily allocated to debt reduction.
Following this strategic divestiture, Solventum has updated its FY2025 guidance, projecting organic sales growth of 2.0-3.0% and raising its adjusted EPS range to $5.88-$6.03. The company expects operating margins at the high end of 20-21% range and reduced net interest expense of $400 million, down from $450 million previously forecasted.
Solventum (NYSE: SOLV) announced its management's participation in two upcoming investor conferences. The company will attend the 2025 Wells Fargo Healthcare Conference in Boston on September 5, 2025, at 10:15 a.m. EDT, and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025, at 10:45 a.m. EDT.
Both fireside chat sessions will be available through live and archived replays on the company's investor relations website at investors.solventum.com.
Solventum (NYSE:SOLV) has launched tender offers to purchase up to $1.75 billion of its outstanding notes. The offers are divided into two pools: Pool 1 with a maximum purchase amount of $1.25 billion covering four series of notes, and Pool 2 with a maximum of $500 million covering two series of notes.
Holders who tender their notes by the Early Tender Date of September 5, 2025, will receive the Total Consideration, which includes an Early Tender Payment of $30 per $1,000 principal amount. The tender offers will expire on September 22, 2025. The Early Settlement Date is expected around September 10, 2025, with the Final Settlement Date around September 25, 2025.
Solventum Corporation (NYSE: SOLV) has announced the pricing of a secondary offering of 8.8 million shares of common stock, which is expected to generate approximately $648 million in gross proceeds for 3M Company, the selling shareholder.
The offering, expected to close around August 15, 2025, is being managed by Goldman Sachs & Co. LLC and BofA Securities. Importantly, Solventum will not receive any proceeds from this transaction as all shares are being sold by 3M Company. The offering is being made through the company's shelf registration statement that became effective on August 13, 2025.